Candriam SCA’s Neurocrine Biosciences NBIX Stock Holding History

Candriam SCA’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.9M	Sell	260,926 -14,138	-5%	-$2.1M	0.2%	109
2026 Q1	$36.2M	Sell	275,064 -18,032	-6%	-$2.39M	0.19%	124
2025 Q4	$41.6M	Buy	293,096 +5,451	+2%	+$790K	0.21%	107
2025 Q3	$40.4M	Sell	287,645 -10,906	-4%	-$1.48M	0.21%	109
2025 Q2	$37.5M	Sell	298,551 -32,289	-10%	-$3.7M	0.22%	98
2025 Q1	$36.6M	Buy	330,840 +26,868	+9%	+$3.4M	0.23%	96
2024 Q4	$41.5M	Sell	303,972 -179,269	-37%	-$22.2M	0.24%	87
2024 Q3	$55.7M	Buy	483,241 +17,774	+4%	+$2.44M	0.32%	66
2024 Q2	$64.1M	Buy	465,467 +149,783	+47%	+$20.5M	0.39%	56
2024 Q1	$43.5M	Sell	315,684 -54,215	-15%	-$7.4M	0.28%	80
2023 Q4	$48.7M	Sell	369,899 -7,339	-2%	-$845K	0.34%	70
2023 Q3	$42.4M	Sell	377,238 -63,178	-14%	-$6.65M	0.3%	72
2023 Q2	$41.5M	Buy	440,416 +23,236	+6%	+$2.27M	0.3%	78
2023 Q1	$38.9M	Buy	417,180 +148,008	+55%	+$15.4M	0.27%	89
2022 Q4	$32.1M	Sell	269,172 -2,309	-0.9%	-$270K	0.22%	110
2022 Q3	$28.8M	Sell	271,481 -59,448	-18%	-$6.03M	0.2%	110
2022 Q2	$32.3M	Buy	330,929 +30,722	+10%	+$2.84M	0.27%	93
2022 Q1	$28.1M	Sell	300,207 -9,706	-3%	-$823K	0.19%	122
2021 Q4	$26.4M	Buy	309,913 +228,400	+280%	+$21M	0.17%	141
2021 Q3	$7.82M	Buy	81,513 +20	+0%	+$1.89K	0.05%	318
2021 Q2	$7.93M	Sell	81,493 -80,376	-50%	-$7.7M	0.05%	320
2021 Q1	$15.9M	Hold	161,869	–	–	0.13%	176
2020 Q4	$16.6M	Buy	161,869 +5,587	+4%	+$540K	0.13%	178
2020 Q3	$15M	Hold	156,282	–	–	0.14%	172
2020 Q2	$19.1M	Sell	156,282 -30,484	-16%	-$3.37M	0.2%	127
2020 Q1	$19.6M	Hold	186,766	–	–	0.22%	103
2019 Q4	$20.1M	Sell	186,766 -17,903	-9%	-$1.87M	0.22%	103
2019 Q3	$18.4M	Sell	204,669 -63,000	-24%	-$5.89M	0.24%	84
2019 Q2	$22.5M	Sell	267,669 -25,000	-9%	-$2.05M	0.28%	75
2019 Q1	$25.8M	Buy	292,669 +64,600	+28%	+$5.4M	0.33%	62
2018 Q4	$16.3M	Buy	228,069 +78,000	+52%	+$7.47M	0.25%	89
2018 Q3	$18.5M	Buy	150,069 +69,969	+87%	+$7.94M	0.25%	99
2018 Q2	$7.87M	Buy	80,100 +15,100	+23%	+$1.35M	0.12%	207
2018 Q1	$5.39M	Sell	65,000 -35,000	-35%	-$2.96M	0.09%	269
2017 Q4	$7.76M	Sell	100,000 -292,000	-74%	-$19.9M	0.13%	192
2017 Q3	$24M	Sell	392,000 -69,000	-15%	-$3.64M	0.42%	55
2017 Q2	$21.2M	Buy	461,000 +214,000	+87%	+$10.4M	0.4%	57
2017 Q1	$10.7M	Buy	247,000 +78,000	+46%	+$3.34M	0.21%	138
2016 Q4	$6.54M	Buy	169,000 +46,000	+37%	+$2.08M	0.15%	168
2016 Q3	$6.23M	Buy	123,000 +6,700	+6%	+$334K	0.15%	164
2016 Q2	$5.29M	Sell	116,300 -2,700	-2%	-$124K	0.14%	171
2016 Q1	$4.68M	Buy	119,000 +7,000	+6%	+$278K	0.12%	207
2015 Q4	$6.34M	Buy	112,000 +21,000	+23%	+$1.07M	0.17%	144
2015 Q3	$3.62M	Sell	91,000 -14,000	-13%	-$677K	0.09%	249
2015 Q2	$5.01M	Sell	105,000 -50,000	-32%	-$2.12M	0.1%	239
2015 Q1	$6.16M	Sell	155,000 -55,000	-26%	-$1.97M	0.12%	216
2014 Q4	$4.69M	Buy	+210,000	New	+$3.98M	0.1%	242

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Candriam SCA's NBIX Position: Q2 2026 in Review

Candriam SCA reduced its Neurocrine Biosciences (NBIX) stake by 5.1% in Q2 2026, selling an estimated $2.1M and leaving 260,926 shares worth $43.9M. The position accounts for 0.2% of the portfolio, ranked #109.

Candriam SCA first reported a position in NBIX in Q4 2014 and has held it in 47 quarters since. The position peaked at $64.1M in Q2 2024. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Candriam SCA held 260,926 shares of Neurocrine Biosciences worth $43.9M as of Q2 2026.
Candriam SCA sold 14,138 Neurocrine Biosciences shares in Q2 2026, an estimated $2.1M.
Neurocrine Biosciences made up 0.2% of Candriam SCA's portfolio in Q2 2026, its #109 holding.
Candriam SCA first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 47 quarters since.
Candriam SCA's Neurocrine Biosciences position peaked at $64.1M in Q2 2024.
775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.